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Abstract
Several cytosolic sulfotransferase enzyme isoforms are functional in placenta but there is limited
information available on the utility of cultured trophoblast cells for studying sulfation. The
trophoblast cell layer constitutes the rate-determining barrier for trans-placental transfer. The
objective of this work was to examine the mRNA expression and enzyme activities of four
sulfotransferase isoforms reported to be functional in human placenta (SULT1A1, SULT1A3,
SULT1E1, and SULT2A1) in primary cytotrophoblast cells and the trophoblast-like BeWo cell line.
Reverse transcription polymerase chain reaction (RT-PCR) was performed to determine mRNA
expression. Enzyme activities were assessed using the following substrates: 4-nitrophenol for
SULT1A1, dopamine for SULT1A3, 17β-estradiol for SULT1E1, and dehydroepiandrosterone for
SULT2A1. For 4-nitrophenol and dopamine sulfation, apparent Km values, response to inhibitors
(2,6-dichloro-4-nitrophenol and sodium chloride), and thermal stability profiles indicated that 4-
nitrophenol and dopamine sulfation in BeWo cells were being mediated by SULT1A1 and SULT1A3,
respectively. SULT1A1 and SULT1A3 were also functional in the cytotrophoblast cells. Both at the
protein and at the mRNA levels, SULT1A1 was more abundant in BeWo cells in comparison to the
primary cytotrophoblast cells. SULT1E1 and SULT2A1 mRNA were not detected in the
cytotrophoblasts. SULT1E1 mRNA was weakly expressed in BeWo but there was negligible
functional activity. Although SULT2A1 mRNA was abundantly expressed in BeWo, Western blot
and enzyme activities revealed that the protein is not expressed in BeWo cells. The results suggest
that the BeWo cells and the cytotrophoblast cells can be used to examine the roles of SULT1A1 and
SULT1A3 in placental metabolism.
1. Introduction
Sulfotransferase (SULT) enzymes catalyze the transfer of a sulfuryl group (SO3-1) from a
physiological donor substrate 3′-phosphoadenosine-5′-phosphosulfate (PAPS) to acceptor
substrates containing hydroxyl, amine, N-hydroxyl, or sulfhydryl groups in a process known
as sulfonation. Sulfoconjugates are generally inactive but in certain cases sulfated metabolites
can be pharmacologically active or potentially carcinogenic [1,2].
Sulfotransferase enzymes can be either cytosolic or membrane-associated. In human tissues,
13 cytosolic SULT isoforms have been identified so far [3] out of which four isoforms have
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been very well characterized. These are the phenolic sulfotransferase isoforms SULT1A1,
SULT1A3, and SULT1E1, and the hydroxysteroid sulfotransferase SULT2A1. SULT1A1
sulfates small, planar phenolic compounds with a high affinity while SULT1A3 sulfates
monoamines with a high affinity. Endogenous substrates of SULT1A1 include 17β-estradiol
and thyroid hormones (T3 and T4), while endogenous substrates of SULT1A3 include
catecholamines (dopamine, epinephrine, and norepinephrine)[3]. Both SULT1A1 and
SULT1A3 also sulfate several medicinal drugs and environmental chemicals which suggests
a major role of the enzymes in xenobiotic elimination[3]. SULT1E1 (also referred to as estrogen
sulfotransferase), exhibits the highest affinity for estrogenic substances among all the
sulfotransferase enzymes [4]. This enzyme sulfates 17β-estradiol at physiological
concentrations. Its physiological functions are most likely concerned with maintaining estrogen
balance, and protection of tissues from the untoward effects of estrogen [5,6]. SULT2A1
sulfates steroid hormones (dehydroepiandrosterone), cholesterol, bile acids, and is
predominantly functional in the adrenal gland [3]. Sulfated dehydroepiandrosterone serves as
the source of estrogens and androgens in peripheral tissues. In the liver, SULT2A1 is
responsible for majority of the bile acid sulfation [4,7]. All four isoforms are functional in the
liver and the intestine [8-10] and tissues such as brain and lung contain several of these isoforms
[11]. The tissue localization supports the hypothesis that these sulfotransferase isoforms play
a major role in modulating xenobiotic exposure.
Sulfation of medicinal drugs has been detected, and subsequently several sulfotransferase
isoforms have been identified in term and mid-gestation human placenta [12,13]. Examination
of placental tissue sections (of both maternal and fetal origin) revealed that the phenolic
sulfotransferase isoforms SULT1A1 and SULT1A3 were functional in all sections. Highest
activity was reported in sections containing syncytiotrophoblast cells [13]. The trophoblast cell
layer consisting of multinucleated syncytiotrophoblast cells and mononucleated
cytotrophoblast cells, is the rate-limiting barrier in the placental transfer of substances[14].
Dehydroepiandrosterone sulfation was attributed to SULT2A1 activity [13]. Although this
study, that examined placental sections, reported low SULT1E1 protein expression in
syncytiotrophoblast fractions, in another study SULT1E1 was found to be localized to the
syncytiotrophoblasts [15]. In addition, other sulfotransferase isoforms are also functional in
syncytiotrophoblasts [16].
Several metabolic enzymes and efflux transporters are functional in trophoblast cells, which
individually as well as in concert, have the ability to modify the extent of fetal exposure to
substances in the maternal circulation [14,17,18]. The process of sulfation introduces a
sulfonate moiety into a molecule. In other tissues, the negatively charged sulfate metabolites
are eliminated by efflux transporters [19,20]. It is likely that a similar concerted pathway for
sulfate metabolite elimination exists in placental tissue as well but this has not yet been
examined. The purpose of this study was to determine whether selected sulfotransferase
enzymes are functional in trophoblast cells, in an effort to comprehend if trophoblast cells can
ultimately be utilized as a suitable model to examine how the placenta inactivates and
eliminates substances in the maternal circulation by sulfation.
Although, the above-mentioned sulfotransferase enzymes have been extensively characterized
in other human tissue, there is only limited information available on whether cultured
trophoblast cells may serve as suitable in vitro models for studying placental sulfation [21].
The objective of this work was to determine the expression and activities of SULT1A1,
SULT1A3, SULT1E1, and SULT2A1 in trophoblast cells. We used primary cytotrophoblast
cells and the BeWo cell line as trophoblast models. The BeWo cell line is derived from a
methotrexate-resistant malignant choriocarcinoma, and in culture consists predominantly of
cytotrophoblast-like cells with a smaller proportion of syncytiotrophoblast-like cells[22].
BeWo cells have also been shown to be adequately representative of placental phase I
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metabolism [17]. This study significantly extends the work of Tamura et al. who demonstrated
sulfation activity in a wild type BeWo cell culture system [21]. Also, we utilized a subclone
of the BeWo cells (b30) that possesses some functional differences with respect to wild type
BeWo cells[23].
2. Materials and methods
2.1. Cell culture materials
The BeWo cell line (clone b30) was obtained from Dr. Alan Schwartz (Washington University,
St. Louis, MO). Penicillin-streptomycin, L-glutamine, and minimal essential medium
nonessential amino acid (MEM-NEAA) solutions were purchased from Invitrogen (Carlsbad,
CA). Heat inactivated fetal bovine serum (FBS) was purchased from Atlanta Biologicals
(Norcross, GA). All other materials and cell culture reagents were from Sigma (St. Louis, MO).
2.2. Cell culture
The BeWo cell line was cultured as described previously [24]. Passages 29 through 45 were
used in this study. Cytotrophoblast cells were obtained from Dr. Joan S. Hunt (University of
Kansas Medical Center, Kansas City, KS). They were isolated from placenta following an
uncomplicated caesarean delivery as per the procedure of Petroff et al. [25] and stored in liquid
nitrogen until further use.
2.3. Homogenate preparation for sulfotransferase assays
BeWo cell homogenate was prepared as described previously with some modifications [26].
Cells at confluence were washed and scraped in phosphate buffered saline (PBS) containing
0.5 mM ethylenediaminetetraacetic acid (EDTA) and 1 mM phenylmethylsulfonylfluoride
(PMSF). Cells were then centrifuged and PBS was aspirated off. Cells were then lysed on ice
in 5 mM potassium phosphate buffer (pH 7.4) containing 1.25 mM EDTA, 2.5 mM
dithiothreitol (DTT), and Complete Mini Protease Inhibitor cocktail tablets (Roche,
Indianapolis, IN) for 20 strokes using a Dounce homogenizer. The lysates were centrifuged at
13,000 × g for 20 minutes at 4°C. The supernatant was further centrifuged at 100,000 × g for
1 hour at 4°C. The resulting high speed supernatant was used for determination of total protein
content. Following this, the high-speed supernatant was diluted in a BSA solution (5 mM
potassium phosphate buffer, pH 7.4, containing 5 mg/mL BSA) at a 1:1 ratio and stored at -80°
C until further use. Cytotrophoblast cell homogenate was prepared in a similar manner.
2.4. Determination of sulfotransferase enzyme activities
Sulfotransferase enzyme assays were performed with the appropriate diagnostic substrates: 4-
nitrophenol for SULT1A1, dopamine for SULT1A3, dehydroepiandrosterone (DHEA) for
SULT2A1, and 17β-estradiol for SULT1E1. Preliminary experiments were optimized to ensure
that product formation was linear with respect to time and protein concentration.
Enzyme assays for SULT1A1 and SULT1A3 were a modification of the method of Foldes and
Meeks [27]. The complete reaction mixture consisted of 0.4 μM [35S]-3′-phosphoadenosine-5′-
phosphosulfate (PAPS, Perkin Elmer, Waltham, MA), varying concentrations of the acceptor
substrates, and BeWo/primary cytotrophoblast protein (20 μg) in 20 mM potassium phosphate
buffer (pH 7.4). The final reaction volume was 150 μL. Controls contained vehicle in place of
the acceptor substrate. Reactions were started by the addition of PAPS to the other components
and incubated at 37°C for 20 minutes. The reaction was terminated by sequential additions of
200 μL of 1:1 0.1 M barium hydroxide:0.1 M barium acetate and 100 μL of 0.1 M zinc sulfate,
and centrifugation of the reaction mixture at 10,000 r.p.m. for 3 minutes. Following this 100
μL each of 0.1M barium hydroxide and 0.1 M zinc sulfate were added, and the reaction mixture
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was centrifuged at 10,000 r.p.m. for 10 minutes. The supernatant was analyzed for the sulfated
product by liquid scintillation counting. Each assay was performed at least in duplicate.
Estradiol (E2) sulfation was measured using a method based on that of Harris et al. with a few
modifications [28]. The reaction mixture consisted of 10 μM PAPS, BeWo cytosolic protein
(50 μg) in a final volume of 200 μL in 100 mM Tris buffer containing 10 mM magnesium
acetate and 0.1 mM EDTA (pH 7.9). Reactions were started by the addition of [2,4,6,7-3H(N)]-
estradiol (0.5 Ci/mmol, Perkin Elmer, Waltham, MA). The rest of the procedure was performed
as outlined previously [28].
Sulfation of 3 μM or 10 μM [1,2,6,7-3H(N)]-dehydroepiandrosterone (diluted to 0.4 Ci/mmol,
Perkin Elmer, Waltham, MA) was measured according to the protocol of Chen et al. [8]. The
reaction mixtures contained BeWo cytosolic protein in the range 50-600 μg.
2.5. Reverse transcription polymerase chain reaction (RT-PCR)
BeWo cells at confluence were washed, scraped in PBS, and then centrifuged to remove the
PBS. Cytotrophoblast cells were retrieved from liquid nitrogen, thawed, and centrifuged to
remove the storage medium. Total RNA was isolated from either BeWo cells or cytotrophoblast
cells, using a commercially available phenol-guanidine isothiocyanate solution (TRIZOL
reagent, Invitrogen, Carlsbad, CA) according to the manufacturer's protocol. An Oligotex
mRNA Mini Kit (Qiagen, Valencia, CA) was used to purify mRNA from total RNA. To
concentrate mRNA prior to the experiment, volume containing 200 ng mRNA was mixed with
1/10th the volume of 3M diethylpyrocarbonate treated sodium acetate (pH 5.2), 2 μL glycogen
(Roche Diagnostics, Indianapolis, IN), and ethanol (at a volume 2.5 fold more than the volume
of mRNA). The mixture was stored overnight at -20°C to precipitate the mRNA. The mixture
was centrifuged at 14,000 rpm for 15 minutes at 4°C. The mRNA pellet was washed in 75%
ethanol and most of the supernatant was aspirated off. The remainder was allowed to evaporate
in room air and the mRNA pellet was reconstituted in RNAse free water. Reverse transcription
and subsequent cDNA amplification were performed with an Access RT-PCR Introductory
System (Promega, Madison, WI) in an Eppendorf Mastercycler. PCR cycle parameters were
according to manufacturer's protocol. The primer sequences for amplifying SULT1A1,
SULT1A3, SULT2A1 and SULT1E1 (Table I) have previously been published [21,29,30]. All
primers were synthesized by the Biotechnology Support Facility at the University of Kansas
Medical Center (Kansas City, KS). Primers for β-actin were obtained from Promega (Madison,
WI).
Electrophoresis of all RT-PCR products was performed at 80 V on a 2% agarose gel. The gel
was post-stained with 0.5 μg/mL ethidium bromide for 45 minutes, washed four times in
distilled water at 10 minute intervals, and viewed with a UV transilluminator.
2.6. Data analyses
Sulfation of both 4-nitrophenol and dopamine exhibited substrate inhibition at high substrate
concentrations. Kinetic constants were determined from a modification of the Michaelis-
Menten equation that incorporates substrate inhibition, which has been outlined as follows.
where, v, Vmax, Km, and [S] represent the sulfation rate, maximal sulfation rate, the apparent
Michaelis-Menten constant, and the utilized substrate concentration respectively. For many
enzymes, a second substrate molecule binds to the active site of the enzyme at high substrate
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concentrations to form an inactive enzyme-substrate complex. Ki represents the dissociation
constant of the substrate from this inhibitory complex. Regression analysis was performed
using the GraphPad Prism software, version 5 (La Jolla, CA).
The IC50 values (inhibitor concentration at which sulfation rate is 50% of the untreated
controls) for 2,6,dichloro-4-nitrophenol were calculated from the Four-Parameter Logistic
Function as follows:
where, y is the sulfation rate, x is the log concentration of the inhibitor and C is the IC50.
Regression analysis was performed using the Sigma Plot software (SPSS, Chicago, IL).
The IC50 values in the presence of sodium chloride and the temperatures at which enzyme
activities were inhibited by 50% were calculated from the Four-Parameter Logistic Function
(Linear) as follows:
where, y is the sulfation rate, x is the concentration of the inhibitor and C is the IC50. Regression
analysis was performed using the Sigma Plot software (SPSS, Chicago, IL).
3. Results
3.1. Sulfotransferase mRNA expression in trophoblast cells
SULT1A1 and SULT1A3 mRNA were expressed in both BeWo cells and cytotrophoblast cells
(Figures 1 and 2). Although semi-quantitative, the results illustrate that SULT1A1 mRNA is
expressed more abundantly in BeWo in comparison to the cytotrophoblast cells. SULT1A3
was equivalently expressed in the two cell types. SULT2A1 mRNA was abundantly expressed
in BeWo but not in the primary cytotrophoblast cells (Figure 2). In contrast, SULT1E1 mRNA
was faintly expressed in BeWo cells and was undetectable in the cytotrophoblast cells (data
not shown).
3.2. Sulfation activities in BeWo cells
The enzyme activities of SULT1A1 and SULT1A3 were tested with 4-nitrophenol and
dopamine respectively. Sulfation of both 4-nitrophenol (0.1-160 μM) and dopamine (0.1-80
μM) exhibited substrate inhibition at higher concentrations (Figures 3 and 4), which is typical
of SULT1A1 and SULT1A3 mediated sulfation respectively [31].
For sulfation of 4-nitrophenol, the apparent Km and Ki values were 0.63 ± 0.21 μM and 21.2
± 8.1 μM, respectively. The apparent Km value in BeWo cells compared well with SULT1A1-
mediated 4-nitrophenol sulfation either in other tissues or with the recombinant protein which
report the Km value to be in the range 0.5-1 μM [26,32-34]. In BeWo, the Km obtained for
dopamine sulfation was 1.1 ± 0.66 μM, while the Ki was 32.9 ± 17.5 μM. Though multiple
articles cite that SULT1A3-mediated sulfation of dopamine exhibits higher apparent Km values
(3-10 μM) [2,26], much lower Km values have also been observed (0.65 μM) [35]. Maximal
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sulfation rates (Vmax) were similar for 4-nitrophenol (9.8 ± 1.3 pmol/min/mg) and dopamine
(10.8 ± 2.4 pmol/min/mg).
It should be mentioned here that at fixed concentrations of 4-nitrophenol or dopamine (2 μM),
biphasic Eadie-Hofstee plots were observed when PAPS concentration was varied. High and
low affinity Km of PAPS in the presence of 4-nitrophenol were (0.034 ± 0.036 μM) and (18.3
± 6.5 μM) respectively. In the presence of dopamine, the Km values for PAPS were (0.029 ±
0.016 μM) and (17.7 ± 4.1 μM) respectively. Control reactions lacked PAPS.
For measuring SULT1A1 and SULT1A3 activities, control reactions contained vehicle in place
of 4-nitrophenol or dopamine. SULT1A1 and SULT1A3 activities were not observed at 20
μM PAPS, which is commonly utilized in sulfotransferase assays. One of the products of the
sulfation reaction, PAP (3′-phosphoadenosine-5′-phosphate), is a potent inhibitor of SULT1A1
and SULT1A3 (Ki= 0.1 ± 0.01 μM and 0.1 ± 0.02 μM respectively)[36]. Accumulation of this
reaction product could be a likely cause of the enzyme inhibition observed at higher PAPS
concentrations. This necessitated performing the enzyme assays at a lower PAPS concentration
(0.4 μM), which is also frequently cited in the literature [27,37,38].
SULT2A1 is reported to exhibit maximal activity towards DHEA in the range 3-10 μM [4]. In
BeWo cells, there was negligible sulfation of DHEA (3 μM and 10 μM). Under the same assay
conditions, purified SULT2A1 readily sulfated DHEA. This indicated that SULT2A1 is not
functional in BeWo cells. Western blots confirmed that SULT2A1 protein is not expressed in
BeWo cells (data not shown). Sulfation of 17β-estradiol (10-30 nM) was negligible (0.02-0.05
pmol/min/mg). This combined with the low mRNA levels of SULT1E1 indicated that
SULT1E1 is not functional in BeWo cells (data not shown).
3.3. Effect of inhibitors 2,6-dichloro-4-nitrophenol (DCNP) and NaCl, and temperature on 4-
nitrophenol and dopamine sulfation in BeWo cells
As there can be overlapping substrate specificities between sulfotransferase isoforms, 4-
nitrophenol and dopamine sulfation activities were further characterized in the presence of
inhibitors 2,6-dichloro-4-nitrophenol (DCNP) and sodium chloride. Typically SULT1A1 is
more sensitive to both DCNP and sodium chloride, than SULT1A3. In BeWo cells, 4-
nitrophenol sulfation was more sensitive to inhibition by DCNP than dopamine sulfation,
whereas both exhibited similar sensitivities to sodium chloride inhibition (Figures 5 and 6).
The IC50 value for 4-nitrophenol sulfation obtained with DCNP (0.052 μM) is similar to
previously cited values (0.4–1.5 μM) [26, 34, 39, 40]. Similarly, the IC50 obtained with sodium
chloride (368 ± 1 mM) was comparable to what has been reported (80-100 mM) [26, 34]. The
IC50 values with DCNP (830 μM) and sodium chloride (303 ± 1.4 mM) for dopamine sulfation
agreed very well with references of SULT1A3-mediated sulfation of dopamine, which put the
values in the range 0.4-0.6 mM and 180-340 mM respectively [2, 26]. Contrary to previous
reports [26, 37], in BeWo cells dopamine sulfation was more sensitive to sodium chloride than
4-nitrophenol sulfation.
SULT1A1 and SULT1A3 exhibit differential thermal stability, and this has led to their
nomenclature as thermostable and thermolabile phenolic sulfotransferase isoforms
respectively. SULT1A1 has been reported to be 50% inactivated between 43-44°C while
SULT1A3 is 50% inactivated between 38.5-40.5°C [2,26,40]. Though there are discrepancies
between studies with regards to the absolute values reported, SULT1A1 is relatively more
thermostable than SULT1A3 [39]. In BeWo cells, 4-nitrophenol and dopamine sulfation were
50% inactivated at 41.5 ± 1.0 °C and at 39.1 ± 1.0 °C, respectively (Figure 7). These
observations matched well with previously reported values and indicated that in BeWo the
enzymes retain their distinctive thermal stability properties.
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Overall, IC50 values obtained in the presence of 2,6,dichloro-4-nitrophenol and sodium
chloride, as well as the temperatures at which enzyme activities were 50% inhibited, agreed
well with previous reports to confirm that 4-nitrophenol and dopamine sulfation in BeWo cells
were being mediated by SULT1A1 and SULT1A3 respectively [2,26,34,39,40]. Also, in BeWo
the biochemical properties of SULT1A1 and SULT1A3 are similar to their properties observed
in other tissues such as platelets, liver, thyroid glands, and bone [2,26,37,40].
3.4. SULT1A1 and SULT1A3 activities in primary cytotrophoblast cells
Among the four sulfotransferase isoforms examined in this study, only the phenolic
sulfotransferase isoforms SULT1A1 and SULT1A3 were functional in BeWo cells. Thus the
enzyme activities of only these two isoforms were determined in the primary cytotrophoblast
cells. Again, 4-nitrophenol and dopamine were used to test for SULT1A1 and SULT1A3
respectively. Sulfation was examined in the presence of 2,6,dichloro-4-nitrophenol (DCNP)
concentrations that previously completely inhibited enzyme activities in BeWo cells (Figure
8). At 1 mM and 4 mM DCNP, sulfation of 4-nitrophenol and dopamine were also completely
inhibited in cytotrophoblast cells. This indicated that 4-nitrophenol sulfation and dopamine
sulfation were being mediated by SULT1A1 and SULT1A3 respectively in the primary
cytotrophoblast cells. SULT1A3 activity was similar (6.9±0.6 pmol/min/mg in BeWo cells vs.
3.8 ± 0.8 pmol/min/mg in primary cytotrophoblast cells) whereas SULT1A1 activity was much
higher in BeWo cells (21.6 ±2 pmol/min/mg in BeWo cells vs. 2.8 ± 2.4 pmol/min/mg in the
primary cytotrophoblast cells).
4. Discussion
Cytosolic sulfotransferase enzymes are functional in whole placental tissue but not much work
has focused on their presence in trophoblast cells which constitute the rate-limiting barrier to
trans-placental transfer [13]. Tamura et al. determined SULT1A1 and SULT1A3 enzyme
activities in BeWo cells using single concentrations of 4-nitrophenol and dopamine [21].
However, there are often overlapping substrate specificities between the sulfotransferase
enzymes. For instance, SULT1A1, SULT1A2, and SULT1B1, all sulfate 4-nitrophenol at low
micromolar concentrations, and thus single concentration determinations can lead to erroneous
identification of sulfotransferase isoforms [32,41]. Our work examines 4-nitrophenol and
dopamine sulfation activities in the presence of inhibitors of these enzymes and extends the
work of Tamura et al [21]. For 4-nitrophenol and dopamine sulfation, apparent Km values,
response to inhibitors and thermal stability profiles agreed well with previously reported
values, to lead to the conclusion that 4-nitrophenol and dopamine sulfation in BeWo cells are
being mediated by SULT1A1 and SULT1A3, respectively. SULT1A1 and SULT1A3 were
also functional in the primary trophoblast cells. Both at the protein and mRNA levels (a semi-
quantitative determination for the latter), SULT1A1 was more abundant in BeWo in
comparison to the primary cytotrophoblast cells, whereas SULT1A3 was equivalently
expressed in the two cell types. SULT1E1 and SULT2A1 mRNA were not detectable in the
primary trophoblast cells and the enzymes were not functional in BeWo cells. There appears
to be some contradiction about the expression of SULT2A1 in placenta. While one study reports
negligible SULT2A1 mRNA in the placenta, Stanley et al reported high DHEA (10 μM)
sulfation rates in fractions rich in syncytiotrophoblasts and attributed this to SULT2A1 [13,
42]. However, as mentioned above sulfotransferases enzymes often exhibit overlapping
substrate specificities, and SULT2A1 is not the only isoform that sulfates DHEA at such
concentrations. Another sulfotransferase isoform SULT2b1b, which also sulfates
hydroxysteroids, is localized primarily to the nuclei of syncytiotrophoblasts [16]. One of the
physiological substrates of SULT2b1b is cholesterol [7] which is the precursor for progesterone
synthesis. SULT2b1b and SULT2A1 exhibit similar affinities for DHEA [16]. It is possible
that the DHEA sulfation activity reported by Stanley et al. [13] was mediated by SULT2b1b.
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Another possible reason for the discrepancy observed in our work and the work of Stanley et
al. [13] with respect to presence of SULT2A1 protein in trophoblast could be differential
enzyme expression between the cytotrophoblasts and syncytiotrophoblasts as has been
observed with several transport proteins [43]. Our results indicated that SULT1E1 is not
functional in BeWo cells. Similar to SULT2A1 there are conflicting reports on placental/
trophoblast SULT1E1 expression. While some studies report much lower activity/mRNA
expression in comparison to SULT1A1/SULT1A3 [13,42], others have demonstrated
SULT1E1 to be localized to syncytiotrophoblasts [15]. One possible reason for observing low
SULT1E1 activity in BeWo cells in this study could be the presence of steroid sulfatase
enzymes, which hydrolyze sulfate molecules. These enzymes exhibit particularly high activity
in placental tissue and have been localized to the syncytiotrophoblasts [15,44].
SULT1A1 sulfates a wide range of substrates that includes steroid hormones, medicinal drugs,
as well as procarcinogens. The physiological functions of this enzyme in the placenta have not
been elucidated, although it has been reported that it is not the source of the high levels of
thyroid hormone sulfates detected in the fetal circulation [13]. One of the endogenous substrates
of SULT1A1 is 17β-estradiol, although SULT1A1 sulfates the hormone at much higher
concentrations than SULT1E1 [45]. As the syncytiotrophoblast secretes increasing amounts
of the 17β-estradiol with advancing gestation [46], it is tempting to speculate that a possible
physiological function of the enzyme is maintaining tissue estrogen balance, at least under
conditions of high local concentrations. Endogenous substrates of SULT1A3 include
catecholamines and catecholestrogens. The majority of plasma catecholamines exist in the
sulfated form [47] and plasma levels of catecholamine sulfates are elevated in disease
conditions such as hypertension and pheochromocytoma [48-50]. The physiological
significance of catecholamine sulfation is not very well understood. However, catecholamine
sulfates are inactive at the adrenergic and dopaminergic receptors and it has been suggested
that conjugation serves as a protective mechanism against the adverse responses that may be
produced from the high circulating levels of catecholamines [7,51-54]. While studies have not
dealt with the specific role of SULT1A3 in the placenta, similar to its function in other tissues,
physiological functions of SULT1A3 in the placenta may be catecholamine inactivation.
Fetal sulfation develops as early as the 14th week of gestation and there are no correlations
between gestation age (14-35 weeks) and fetal sulfotransferase activity [55]. Several studies
report fetal SULT1A1 and SULT1A3 activities to be higher or similar to placental activity
[55,56]. Nevertheless, the SULT1A family also appears to be well developed in the placenta
and likely acts as a support of fetal metabolism for fetal protection.
In conclusion our work establishes the phenolic sulfotransferase isoforms SULT1A1 and
SULT1A3 to be functional in BeWo cells and in primary cultures of cytotrophoblast cells. A
lot of the work on placental metabolism has focused on the effects of cigarette smoke, medicinal
drugs, and environmental chemicals on placental enzyme activity, as a way of determining if
this may be related to fetal toxicity. There has not been a lot of focus on the effects of foreign
chemicals on placental sulfotransferase activity. SULT1A1 catalyses the sulfation of several
procarcinogens such as N-hydroxylated aromatic amines, nitroalkanes, and benzylic alcohols
to produce nucleophilic DNA adducts [1,57]. The functional activities of SULT1A1 and
SULT1A3 in BeWo cells suggests that this cell line can be used as a suitable model for studying
placental sulfotransferase induction/inhibition as a basis for developing an understanding of
the role of these enzymes in physiological and disease processes. Also, the BeWo cells express
several efflux transporters and it is likely that one or more of these eliminate sulfate metabolites.
Thus the BeWo cell line can be used to demonstrate how firstly sulfation, and secondly,
elimination of sulfate metabolites, serves to protect the fetus.
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Figure 1. Reverse transcription polymerase chain reaction (RT-PCR) analysis of SULT1A1 in
BeWo cells and in primary cytotrophoblast cells
200 ng mRNA was used for reverse transcription and polymerase chain reaction amplification
of SULT1A1. Expected size: SULT1A1 (987 bp).
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Figure 2. Reverse transcription polymerase chain reaction (RT-PCR) analyses of SULT1A3 and
SULT2A1 in BeWo cells and in primary cytotrophoblast cells
200 ng mRNA was used for reverse transcription and polymerase chain reaction amplification
of SULT1A3 and SULT2A1. Expected sizes: SULT1A3 (987 bp), SULT2A1 (872 bp).
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Figure 3. Sulfation of 4-nitrophenol (pmol/min/mg protein) in BeWo cells as a function of 4-
nitrophenol concentration
The figure represents a fit to the substrate inhibition equation (section 2.6). Each assay was
repeated at least twice and each point represents the mean ± S.E.M. of three or more
determinations. Kinetic parameters were as follows: Km = 0.63 ± 0.21 μM, Ki = 21.2 ± 8.1
μM.
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Figure 4. Sulfation of dopamine (pmol/min/mg protein) in BeWo cells as a function of dopamine
concentration
The figure represents a fit to the substrate inhibition equation (section 2.6). Each assay was
repeated at least twice and each point represents the mean ± S.E.M. of three or more
determinations. Kinetic parameters were as follows: Km = 1.1 ± 0.66 μM, Ki = 32.9 ± 17.5
μM.
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Figure 5. Effect of 2,6,-dichloro-4-nitrophenol on sulfotransferase activities in BeWo cells
The effect of 2,6-dichloro-4-nitrophenol (DCNP) on 4-nitrophenol (solid circles) and
dopamine (open circles) sulfation activities was determined in BeWo cells. Enzyme activity
in the presence of the inhibitor was expressed as a percentage of the activity in the absence of
the inhibitor. The IC50 values for 4-nitrophenol and dopamine were 0.05 μM and 830 μM
respectively. Each assay was repeated twice and each point represents mean ± S.E.M of three
or more determinations.
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Figure 6. Effects of sodium chloride on sulfotransferase activities
The effect of NaCl on 4-nitrophenol (solid circles) and dopamine (open circles) sulfation
activities was determined in BeWo cells. Enzyme activity in the presence of the inhibitor was
expressed as a percentage of the activity in the absence of the inhibitor. The IC50 values for 4-
nitrophenol and dopamine were 368 ± 1 mM and 303 ± 1.4 mM respectively. Each assay was
repeated twice and each point represents mean ± S.E.M of three or more determinations.
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Figure 7. Thermal stability of 4-nitrophenol (solid circles and broken line) and dopamine (open
circles and solid line) sulfation activities in BeWo cells
The net sulfotransferase activity was expressed as a percentage of the basal (unheated)
activities. The 50% inactivation temperatures (T50) were 41.5 ± 1.0 °C and at 39.1 ± 1.0 °C
for 4-nitrophenol and dopamine respectively. Each point represents mean ± S.E.M of three or
more determinations.
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Figure 8. Sulfation activities of 4-nitrophenol (4 μM) and dopamine (1 μM) in primary
cytotrophoblast cells
Sulfotransferase activities were measured in the presence and in the absence of 1 mM and 4
mM 2,6,-dichloro-4-nitrophenol (DCNP). At these concentrations, DCNP previously
completely abolished 4-nitrophenol and dopamine sulfation in BeWo cells. DCNP also
completely inhibited 4-nitrophenol and dopamine sulfation in the primary trophoblast cells to
indicate that 4-nitrophenol and dopamine sulfation are being mediated by SULT1A1 and
SULT1A3 respectively.
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Table I
Primer sequences used for reverse transcribing sulfotransferase mRNA and expected base
pair sizes of the reaction products
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